Behavioral dysfunction in Parkinson's disease

Clinical Neuroscience

Volumn 5, Issue 2, 1998, Pages 87-93

  Friedman, Joseph H ^a,b,c  

^a Department of Clinical Neurosciences ^*  (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Anxiety; Atypical antipsychotics; Dementia; Depression; Drug induced psychosis; Parkinson personality

Indexed keywords

ANTIPARKINSON AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIOR DISORDER; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEMENTIA; DEPRESSION; DRUG INDUCED DISEASE; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LANGUAGE DISABILITY; PARKINSON DISEASE; PHENOMENOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW;

DEMENTIA; DEPRESSION; ELECTROCONVULSIVE THERAPY; HALLUCINATIONS; HUMAN; MENTAL DISORDERS; PARKINSON DISEASE; PERSONALITY; PSYCHOTIC DISORDERS;

EID: 0032470584     PISSN: 10656766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Bodner RA, Lynch T, Lewis L, Kahn D (1995): Serotonin syndrome. Neurology 45:219-223.
2. Booth G (1948): Psychodynamics in parkinsonism. Psychosom Med 10:1-14.
3. Brod TM (1989): Fluoxetine and extrapyramidal side effects. Am J Psychiatry 146: 1352-1353.
4. Caley CF, Friedman JH (1992): Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 53:278-282.
5. Carter JH, Stewart BJ, Archold PG, and the Parkinson Study Group (1998): Living with a person who has Parkinson's disease: the spouse's perspective by stage of the disease. Mov Disord 33:20-28.
6. Casey DE (1990): What makes a neuroleptic atypical? In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press, p 241-251.
7. Cummings JL (1992): Depression and Parkinson's disease: a review. Am J Psychiatry 149:443-454.
8. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: Am Psychiatric Assoc.
9. Doonief G, Mirabellow E, Bell K, Stern Y, Mayeux R (1992): An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 49:305-307.
10. Eatough VM, Kempster PA, Stern GM, Lees AJ (1990): Premorbid personality and idiopathic Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MB, editors. Parkinson's disease: anatomy, pathology and therapy. Advances in neurology, vol 53. New York: Raven Press, p 335-337.
11. Ehman TS, Beninger RJ, Gawel MJ (1990): Depressive symptoms in Parkinson's disease: a comparison of subjects. J Geriatr Psychiatry Neurol 2:3-9.
12. Factor SA, Molho ES, Podskalny GD, Brown D (1995): Parkinson's disease: drug-induced psychiatric states. In: Weiner WJ, Lang AE, editors. Behavioral neurology of movement disorders. Advances in neurology, vol 65. New York: Raven Press, p 115-138.
13. Fernandez HH, Friedman JH, Jacques CJ (1999): Quetiapine in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord (in press).
14. Flint AJ (1994): Epidemiology and co-morbidity of anxiety disorders in the elderly. Am J Psychiatry 151:640-649.
15. Friedman JH (1991): Management of levodopa psychosis. Clin Neuropharmacol 14:283-295.
16. Friedman JH, Goldstein SM (1998): Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 50:1195-1196.
17. Friedman JH, Goldstein SM, Jacques C (1998): Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open-label pilot trial. Clin Neuropharmacol 21:285-288.
18. Glosser G, Clark C, Freundlich B, Kliner-Krenzel L, Flaherty P, Stern M (1995): A controlled investigation of current and premorbid personality: characteristics of Parkinson's disease patients. Mov Disord 10:201-206.
19. Goetz CG, Stebbins GT (1993): Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43:2227-2229.
20. Goetz CG, Stebbins GT (1995): Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45:669-671.
21. Goetz CG, Tanner CM, Klawans HL (1984): Buproprion in Parkinson's disease. Neurology 34:1092-1094.
22. Gotham A-M, Brown RG, Marsden CD (1986): Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 49:381-389.
23. Hauser RA, Zesiewicz TA (1997): Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 12:756-759.
24. Heberlein I, Ludin HP, Schloz J, Vieregge P (1998): Personality depression and premorbid lifestyle in twin pairs discordant for Parkinson's disease. J Neurol Neurosurg Psychiatry 64:262-266.
25. Henderson R, Kurlan R, Kersun JM, et al (1992): Preliminary examination of the co-morbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 4:257-266.
26. Jankovic J, McDermott M, Carter J (1990): Variable expression of Parkinson's disease: a base-line analysis of the DATA-TOP cohort. Neurology 40:1529-1534.
27. Jellinger KA (1997): Morphological substrates of dementia in parkinsonism: a critical update. J Neural Transm (Suppl) 51:57-82.
28. Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera, Cabrera-Valdivia (1994): Parkinsonism exacerbated by paroxetine. Neurology 44:2406.
29. Jimenez-Jimenez FJ, Talon-Barranco A, Orti-Pareja M, Zurdo M, Porta J, Molina JA (1998): Olanzapine can worsen parkinsonism. Neurology 50:1183-1184.
30. Klaassen T, Verhey FR, Sneijdero GH, Rozendaal N, de Vet NC, Von Praag HM (1995): Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 7:281-286.
31. Laitinen L (1969): Desipramine in the treatment of Parkinson's disease. Acta Neurol Scand 45:109-111.
32. Mattila PM, Roytta M, Torikka H, Dickson DW, Rinne JO (1998): Cortical Lewy bodies and Alzheimer type changes in patients with Parkinson's disease. Acta Neuropatholo (Berl) 95:576-582.
33. Mayeux R, Stern Y (1983): Intellectual dysfunction and dementia in Parkinson's disease. In: Mayeux R, Rosen WG, editor. The dementias. New York: Raven Press.
34. Mayeux R, Stern Y, Cote L, Williams JBW (1984): Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 34:642-646.
35. Mayeux R, Denaro J, Hemenglido N, Marder K, Tang MX, Cote LJ, Stern Y (1992): A population-based investigation of Parkinson's disease with or without dementia. Arch Neurol 49:492-497.
36. McCance-Katz EF, Marek KL, Price LH (1992): Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 42:1813-1814.
37. Meco G, Alessandri A, Guistini P, Bonifati V (1997): Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open label long term study. Mov Disord 12:610-612.
38. Mendelsohn GA, Dakof GA, Skaff M (1995): Personality change in Parkinson's disease patients: chronic disease and aging. J Pers 63:233-257.
39. Menza MA, Golbe LI, Cody RA, Forman NE (1993): Dopamine-related personality traits in Parkinson's disease. Neurology 45:505-508.
40. Menza MA, Robertson-Hoffman DE, Bonapase AS (1994): Parkinson's disease and anxiety: co-morbidity with depression. Biol Psychiatry 34:465-470.
41. Mindham RHS (1970): Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 33:188-191.
42. Moellentine C, Rummons T, Ahlskog JE, Harmsen WS, Suman VJ, O'Connor MK, Black PL, Pileggi T (1998): Effectiveness of ECT in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 10:187-193.
43. Molho ES, Factor SA (1998): Worsening of motor features of Parkinson's disease with olanzapine. Mov Disord 13(Suppl 2):256.
44. Montastruc JL, Fabre N, Blin O (1995): Does fluoxetine aggravate Parkinson's disease? A prospective study. Mov Disord 10:355-357.
45. Okazaki H, Lipkin LE, Aronson SM (1961): Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 20:237-244.
46. Perl DP, Olanow CW, Calne D (1998): Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol 44(Suppl 1):S19-S32.
47. Poewe W, Karamat E, Kemmler GW, Gerstonbrand F (1990): The premorbid personality of patients with Parkinson's disease: a comparative study with healthy controls and patients with essential tremor. In: Streifler MB, et al., editors. Ann Neurol Ibid p 339-342.
48. PSG (Parkinson Study Group) (1999): Low dose clozapine for the treatment of drug-induced psychosis in idiopathic Parkinson's disease: results of the double blind, placebo controlled PSYCLOPS trial. N Engl J Med (in press).
49. Rich SS, Friedman JH, Ott BR (1995): Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 56: 556-559.
50. Richard IH, Schiffer RB, Kurlan R (1996): Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 8:383-392.
51. Richard IH, Kurlan R, Tanner CM, Factor SA, Hubble J, Sucherowsky O, Waters C (1997a): Serotonin syndrome and the combined use of deprenyl (selcgilinc) and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 48:1070-1077.
52. Richard IH, Kurlan R, and the Parkinson Study Group (1997b): A survey of antidepressant drug use in Parkinson's disease. Neurology 49:1168-1170.
53. Salzman C (1993): Pharmacologic treatment of depression in the elderly. J Clin Psychiatry 54:2(Suppl):23-28.
54. Sanchez-Ramos JR, Ortoll R, Paulson GW (1996): Visual hallucinations associated with Parkinson's disease. Arch Neurol 53:1265-1268.
55. Sands IJ (1942): The type personality susceptible to Parkinson's disease. J Mt Sinai Hosp 1942:792-744.
56. Savage CR (1997): Neuropsychology of subcortical dementias. Psychiatr Clin N Am 20:911-931.
57. Shea C, MacKnight C, Rockwood K (1998): Donepezil for treatment of dementia with Lewy bodies: a case of nine patients. Int Psychogeriatr 10:229-238.
58. Shulman LM, Singer C, Liefer R, Weiner WJ (1996): Therapeutic efficacy of sertraline in patients with Parkinson's disease. Mov Disord 1:12 (abstract).
59. Siemens ER, Shekhan A, Quid K (1993): Anxiety and motor performance in Parkinson's disease. Mov Disord 8:501-506.
60. Simons JA (1996): Fluoxetine in Parkinson's disease. Mov Disord 11:581-582.
61. Singer E (1973): The effect of treatment with levodopa on Parkinson's patients' social functioning and outlook on life. J Chronic Dis 27:581-594.
62. Starkstein SE, Prezios TJ, Bolduc PL, Robinson RG (1990): Depression in Parkinson's disease. J Neuro Ment Disord 178: 127-131.
63. Stein MB, Heuser IJ, Juncos JL, Uhde TW (1990): Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 147:217-220.
64. Steur ENH (1993): Increase of Parkinson disability after fluoxetine medication. Neurology 43:211-213.
65. Strang RR (1965): Imipramine in the treatment of parkinsonism: a double blind placebo study. Br Med J 2:33-34.
66. Sudarsky L, Morris J, Romero J, Washe TM (1989): Dementia in Parkinson's disease. The problem of clinicopathological correlation. J Neuropsychiatry 1:159-166.
67. Taylor AE, St. Cyr JA (1995): The neuropsychology of Parkinson's disease. Brain Cogn 28:281-296.
68. Tison F, Dartiques JF, Auriacombe S, Letenneur L, Boller F, Alpervitch A (1995): Dementia in Parkinson's disease: a population based study in ambulatory and institutionalized individuals. Neurology 45:705-708.
69. Tom T (1998): Depression in Parkinson's disease. Drugs Aging 12:55-74.
70. Torack R, Morris JC (1988): The association of vential tegmental area histopathology with adult dementia. Arch Neurol 45:497-501.
71. Troster AI, Stolp LD, Paolo AM, Fields JA, Koller WC (1995): Neuropsychological impairment in Parkinson's disease with or without depression. Arch Neurol 52: 1164-1169.
72. Warburton J (1967): Depressive symptoms in Parkinson's patients referred for thalamotomy. J Neurol Neurosurg Psychiatry 30:368-370.
73. Weiner WJ, Minagar A, Shulman L (1998): Olanzapine for the treatment of hallucinations/delusions in Parkinson's disease. Mov Disord 13(Suppl 2):62.
74. Wengel SP, Burke WJ, Pfeiffer RF, Roccaforte WH, Paige SR (1998): Maintenance electroconvulsive therapy for intractable Parkinson's disease. Am J Geriatr Psychiatry 6:263-269.
75. Wolters EC, Hurwitz RE, Mak E, Teal P, Peppard FR, Remick R, Calne S, Calne DB (1990): Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40:832-834.
76. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmens PL (1996): Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 47:1085-1087.
77. Workman RH Jr, Orengo CA, Bakey AA, Molinari VA, Kunik ME (1997): The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 9:594-597
78. Zweig RM, Cardilio JE, Cohen M, Giere S, Hedreen JC (1993): The locus ceruleus and dementia in Parkinson's disease. Neurology 43:986-991.